Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis

Shruti Kate,1 Anuradha Chougule,2 Amit Joshi,1 Vanita Noronha,1 Vijay Patil,1 Rohit Dusane,3 Leena Solanki,1 Priyanka Tiwrekar,2 Vaishakhi Trivedi,1 Kumar Prabhash1 1Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India; 2Department of Molecular Pathology, Tata Memorial...

Full description

Bibliographic Details
Main Authors:	Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R, Solanki L, Tiwrekar P, Trivedi V, Prabhash K
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-01-01
Series:	Lung Cancer: Targets and Therapy
Subjects:	Uncommon EGFR mutations Advanced NSCLC Tyrosine Kinase Inhibitors Complex EGFR mutations Dual EGFR mutations
Online Access:	https://www.dovepress.com/outcome-of-uncommon-egfr-mutation-positive-newly-diagnosed-advanced-no-peer-reviewed-article-LCTT

Similar Items

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon EGFR Mutations
by: Christoforos Astaras, et al.
Published: (2020-03-01)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
by: Vito Longo, et al.
Published: (2021-07-01)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
by: Yue Hao, et al.
Published: (2023-08-01)

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients
by: Gang Guo, et al.
Published: (2021-04-01)

Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review
by: Puchun Er, et al.
Published: (2017-08-01)

Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis
by: Anurag Mehta, et al.
Published: (2021-01-01)

Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
by: Pascal Wang, et al.
Published: (2022-07-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
by: How-Wen Ko, et al.
Published: (2022-10-01)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
by: Stephen V. Liu, et al.
Published: (2023-09-01)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
by: Keunchil Park, et al.
Published: (2021-07-01)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
by: Liping Kang, et al.
Published: (2023-02-01)

The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
by: Jiarong Tan, et al.
Published: (2021-08-01)

Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study
by: Yung-Hsuan Chen, et al.
Published: (2019-10-01)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
by: James Chih-Hsin Yang, et al.
Published: (2022-04-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor  Receptor Mutations in Non-small Cell Lung Cancer
by: Xue YANG, et al.
Published: (2015-08-01)

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
by: Rui Kitadai, et al.
Published: (2022-05-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023-06-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
by: Ayako Morita, et al.
Published: (2021-04-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel
Published: (2020-03-01)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01)

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)
by: Vázquez S, et al.
Published: (2016-02-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC
by: Wufei Chen, et al.
Published: (2021-12-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
by: Obradovic Jasmina, et al.
Published: (2012-12-01)

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
by: Di Hu, et al.
Published: (2023-06-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
by: Syahruddin E, et al.
Published: (2018-03-01)

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
by: Yen‐Ting Lin, et al.
Published: (2024-01-01)

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
by: Giulia Pretelli, et al.
Published: (2023-05-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Wei Dong, et al.
Published: (2022-11-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
by: Antonio Passaro, et al.
Published: (2021-07-01)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
by: Xingxiang Pu, et al.
Published: (2023-10-01)

Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer
by: Vinh Thanh Tran, et al.
Published: (2020-08-01)